Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 431-439

  Blum, Joanne L ^e   Kohles, Joseph ^a   McKenna, Edward ^a   Scotto, Nana ^b   Hu, Sylvia ^a   Odom, Dawn ^c   Kaye, James A ^c   Glück, Stefan ^d  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c RTI HEALTH SOLUTIONS   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e NONE

Author keywords

Age; Capecitabine; Chemotherapy; Clinical trial; Metastatic breast cancer; Tolerability

Indexed keywords

CAPECITABINE; DOCETAXEL;

ADULT; AGE; AGED; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; STOMATITIS; TREATMENT RESPONSE; VISCERAL METASTASIS; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 78650989470     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1222-3     Document Type: Article

References (21)

1. U.S. Centers for Disease Control and Prevention: Breast cancer rates by age. http://www.cdc.gov/cancer/breast/statistics/age.htm
2. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 598 225 249 10.3322/caac.20006
3. WF Anderson I Jatoi ME Sherman 2009 Qualitative age interactions in breast cancer studies: mind the gap J Clin Oncol 27 5308 5311 10.1200/JCO.2009.22.9450 19826117
4. K Christman HB Muss LD Case V Stanley 1992 Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment] JAMA 268 57 62 1:STN:280:DyaK38zgtVylsA%3D%3D 10.1001/jama.268.1.57 1608114
5. G Pentheroudakis G Fountzilas HP Kalofonos Hellenic Cooperative Oncology Group, et al. 2008 Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors Crit Rev Oncol Hematol 66 237 247 10.1016/j.critrevonc.2007.12.003 18243010
6. HB Muss DA Berry C Cirrincione, et al. 2007 Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience J Clin Oncol 25 3699 3704 1:CAS:528:DC%2BD2sXhtVeqt7fP 10.1200/JCO.2007.10.9710 17704418 (Pubitemid 47372610)
7. GW Sledge N Robert JA Sparano, et al. 1995 Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer Semin Oncol 22 3 Suppl 6 105 108 7597425
8. ® (capecitabine) [prescribing information]: Genentech, Inc. South San Francisco, CA; 2009
9. GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky WC Wood 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592 10.1200/JCO.2003.08. 013 12586793 (Pubitemid 46621890)
10. Stockler M, Sourjina T, Grimison P et al (2007) A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 25:39s (18S; abstr 1031)
11. J O'Shaughnessy D Miles S Vukelja, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
12. JL Blum SE Jones AU Buzdar, et al. 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493 1:CAS:528:DyaK1MXht1Wmurw%3D 10080589
13. JL Blum V Dieras PM Lo Russo J Horton O Rutman A Buzdar B Osterwalder 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768 1:CAS:528:DC%2BD3MXosV2qsLw%3D 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A 11745247 (Pubitemid 32952493)
14. DC Talbot V Moiseyenko S Van Belle, et al. 2002 Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 1367 1372 1:CAS:528:DC%2BD38XkvVKjsLo%3D 10.1038/sj.bjc.6600261 11986765 (Pubitemid 34548055)
15. JA O'Shaughnessy J Blum V Moiseyenko, et al. 2001 Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 1247 1254 10.1023/A:1012281104865 (Pubitemid 32994752)
16. L Balducci 2001 The geriatric cancer patient: equal benefit from equal treatment Cancer Control 8 Suppl 2 1 25 1:STN:280:DC%2BD3MzlsFOlsQ%3D%3D 11326165
17. NK Ibrahim DK Frye AU Buzdar RS Walters GN Hortobagyi 1996 Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome Arch Intern Med 156 882 888 1:CAS:528: DyaK28Xis1Slurc%3D 10.1001/archinte.156.8.882 8774207 (Pubitemid 26120594)
18. HB Muss DA Berry CT Cirrincione, et al. 2009 Adjuvant chemotherapy in older women with early-stage breast cancer N Engl J Med 360 2055 2065 1:CAS:528:DC%2BD1MXmtVagsbw%3D 10.1056/NEJMoa0810266 19439741
19. MF Rimawi PB Shetty HL Weiss R Schiff CK Osborne GC Chamness RM Elledge 2010 Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Cancer 116 1234 1242 10.1002/cncr.24816 20082448
20. F Heitz P Harter HJ Lueck A Fissler-Eckhoff F Lorenz-Salehi S Scheil-Bertram A Traut A du Bois 2009 Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases Eur J Cancer 45 2792 2798 1:CAS:528:DC%2BD1MXhtlSqsL3M 10.1016/j.ejca.2009.06.027 19643597
21. J Chang GM Clark DC Allred S Mohsin G Chamness RM Elledge 2003 Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor Cancer 97 545 553 10.1002/cncr.11083 12548595 (Pubitemid 36125831)